Tgtx discussion stock price?
TGTX Stock 12 Months Forecast
Based on 6 Wall Street analysts offering 12 month price targets for TG Therapeutics in the last 3 months. The average price target is $27.40 with a high forecast of $45.00 and a low forecast of $6.00. The average price target represents a 73.58% change from the last price of $15.79.
What is the future of TGTX stock?
TGTX Stock 12 Months Forecast
Based on 6 Wall Street analysts offering 12 month price targets for TG Therapeutics in the last 3 months. The average price target is $27.40 with a high forecast of $45.00 and a low forecast of $6.00. The average price target represents a 73.58% change from the last price of $15.79.
Is TGTX a buy or sell?
TG Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
What is the TGTX forecast for 2024?
According to our current TGTX stock forecast, the value of TG Therapeutics shares will rise by 1.72% and reach $ 16.07 per share by February 1, 2024. According to our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear).
What is the CNN forecast for TGTX?
TG Therapeutics Inc (NASDAQ:TGTX)
The 8 analysts offering 12-month price forecasts for TG Therapeutics Inc have a median target of 30.75, with a high estimate of 45.00 and a low estimate of 7.00.
Will TGTX go back up?
On average, Wall Street analysts predict that Tg Therapeutics's share price could reach $26.00 by Jan 11, 2025. The average Tg Therapeutics stock price prediction forecasts a potential upside of 64.56% from the current TGTX share price of $15.80.
Why is TGTX going down?
Sales of a new multiple sclerosis drug from TG Therapeutics (TGTX) crushed analysts' expectations, but TGTX stock tumbled on lackluster 2024 guidance. For the year, the biotech company expects $220 million to $260 million in sales of Briumvi, its new treatment for relapsing forms of multiple sclerosis.
Will TGTX get FDA approval?
TGTX announced that the FDA has approved its anti-CD20 monoclonal antibody, Briumvi (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Who owns TGTX stock?
Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, XBI - SPDR(R) S&P(R) Biotech ETF, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Paradigm Biocapital Advisors LP, NAESX - Vanguard Small-Cap Index Fund Investor Shares, IWM - iShares Russell 2000 ETF, Wellington ...
Who are TGTX competitors?
The main competitors of TG Therapeutics include Xenon Pharmaceuticals (XENE), Bausch Health Companies (BHC), Prestige Consumer Healthcare (PBH), Evotec (EVO), HUTCHMED (HCM), Gemini Therapeutics (GMTX), CymaBay Therapeutics (CBAY), Galapagos (GLPG), Amphastar Pharmaceuticals (AMPH), and MoonLake Immunotherapeutics ( ...
Does TGTX pay a dividend?
Tg Therapeutics (NASDAQ: TGTX) does not pay a dividend.
What is the target stock price forecast for 2024?
Target Stock Price Forecast 2024-2025
Target price started in 2024 at $142.42. Today, Target traded at $142.53, so the price decreased by 0% from the beginning of the year. The forecasted Target price at the end of 2024 is $187 - and the year to year change +31%. The rise from today to year-end: +31%.
What is the TSM 5 year forecast?
TSM stock price stood at $117.26
According to the latest long-term forecast, TSM price will hit $150 by the end of 2024 and then $200 by the middle of 2027. TSM will rise to $250 within the year of 2029, $300 in 2031 and $350 in 2035.
What is the stock price forecast for Regeneron in 2030?
Regeneron Pharmaceuticals Stock Prediction 2030
In 2030, the Regeneron Pharmaceuticals stock will reach $ 2,017.13 if it maintains its current 10-year average growth rate. If this Regeneron Pharmaceuticals stock prediction for 2030 materializes, REGN stock willgrow 112.58% from its current price.
Will ADXS go up?
Stock Price Forecast
The 1 analysts offering 12-month price forecasts for Ayala Pharmaceuticals Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate represents a +577.97% increase from the last price of 0.59.
Is Outlook Therapeutics a buy?
Outlook Therapeutics's analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
Who is the founder of TGTX?
Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Is Nvidia a buy or sell?
Nvidia has a conensus rating of Strong Buy which is based on 34 buy ratings, 4 hold ratings and 0 sell ratings. What is Nvidia's price target? The average price target for Nvidia is $675.40. This is based on 38 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
Who is the CEO of TGTX?
Michael S. Weiss founded and has served as the Company's Chairman, President and CEO since December 2011.
What does TG Therapeutics do?
Related keylists. TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and various autoimmune diseases.
What is Regeneron stock target?
| High | $1,125.00 |
|---|---|
| Median | $980.00 |
| Low | $700.00 |
| Average | $961.63 |
| Current Price | $930.00 |
Is Well Health Technologies a buy?
WELL Health Technologies has received a consensus rating of Moderate Buy.
How much does Briumvi cost a year?
Recently, TG Therapeutics announced that it plans to make Briumvi the most accessible therapy in its class by pricing it at $59,000 per year.
Is briumvi available in usa?
Briumvi (ublituximab-xiiy) is a cellular cytolytic that binds to the CD20 on the surface of the B Lympochites indicated for the treatment of Multiple Sclerosis (MS)1. Briumvi (ublituximab-xiiy) was approved by the FDA in December 20222.
How much does Briumvi cost?
It is a monoclonal antibody. Get Briumvi for as low as $31,299.84, which is 14% off the average retail price of $36,427.98 for the most common version, by using a GoodRx coupon.
